journal article·2023-09Open access

Polyoxazoline‐Based Nanovaccine Synergizes with Tumor‐Associated Macrophage Targeting and Anti‐PD‐1 Immunotherapy against Solid Tumors

Ana I. Matos, Carina Peres, Barbara Carreira, Liane I. F. Moura, Rita C. Acúrcio, Theresa Vogel, Erik Wegener, Filipa Ribeiro, Marta B. Afonso, Fábio M. F. Santos, Águeda Martínez‐Barriocanal, Diego Arango, Ana S. Viana, Pedro M. P. Góis, Liana C. Silva, Cecília M. P. Rodrigues, Luis Graca, Rainer Jordan, Ronit Satchi‐Fainaro, Helena F. Florindo

Advanced Science· Volume 10· Issue 25

Abstract

Abstract Immune checkpoint blockade reaches remarkable clinical responses. However, even in the most favorable cases, half of these patients do not benefit from these therapies in the long term. It is hypothesized that the activation of host immunity by co‐delivering peptide antigens, adjuvants, and regulators of the transforming growth factor (TGF)‐β expression using a polyoxazoline (POx)‐poly(lactic‐co‐glycolic) acid (PLGA) nanovaccine, while modulating the tumor‐associated macrophages (TAM) function within the tumor microenvironment (TME) and blocking the anti‐programmed cell death protein 1 (PD‐1) can constitute an alternative approach for cancer immunotherapy. POx‐Mannose (Man) nanovaccines generate antigen‐specific T‐cell responses that control tumor growth to a higher extent than poly(ethylene glycol) (PEG)‐Man nanovaccines. This anti‐tumor effect induced by the POx‐Man nanovaccines is mediated by a CD8+‐T cell‐dependent mechanism, in contrast to the PEG‐Man nanovaccines. POx‐Man nanovaccine combines with pexidartinib, a modulator of the TAM function, restricts the MC38 tumor growth, and synergizes with PD‐1 blockade, controlling MC38 and CT26 tumor growth and survival. This data is further validated in the highly aggressive and poorly immunogenic B16F10 melanoma mouse model. Therefore, the synergistic anti‐tumor effect induced by the combination of nanovaccines with the inhibition of both TAM‐ and PD‐1‐inducing immunosuppression, holds great potential for improving immunotherapy outcomes in solid cancer patients.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer Immunotherapy and Biomarkers · Immune cells in cancer · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Grouf of BioNanoSciences ‐ Drug Delivery and Immunoengineering, Research Institute for Medicines (iMed.ULisboa), Department of Pharmacy, Pharmacology and Health Technologies Faculty of Pharmacy Universidade de Lisboa Lisbon 1649‐003 Portugal

Faculdade de Medicina, Instituto de Medicina Molecular João Lobo Antunes, Lisbon Academic Medical Center Universidade de Lisboa Lisbon 1649‐028 Portugal

Department of Chemistry, Faculty of Chemistry and Food Chemistry, School of Science Technische Universität Dresden 01062 Dresden Germany

Group of Biomedical Research in Digestive Tract Tumors CIBBIM‐Nanomedicine Vall d'Hebron Research Institute (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona 08035 Spain

Group of Molecular Oncology Lleida Biomedical Research Institute (IRBLleida) Lleida 25198 Spain

Centro de Química Estrutural Departamento de Química e Bioquímica Institute of Molecular Sciences Faculty of Sciences Universidade de Lisboa Lisbon 1749‐016 Portugal

Department of Physiology and Pharmacology Faculty of Medicine Sagol School of Neuroscience Tel Aviv University Tel Aviv 69978 Israel

Funding

Israel Science Foundation · Melanoma Research Alliance

References (94)

Show source-provided references
1. 10.1126/sciadv.aaw607110.1126/sciadv.aaw6071 ↗
2. 10.1038/s41467-017-01386-710.1038/s41467-017-01386-7 ↗
3. 10.1016/j.jconrel.2021.05.00110.1016/j.jconrel.2021.05.001 ↗
4. 10.1016/j.biomaterials.2018.05.02210.1016/j.biomaterials.2018.05.022 ↗
5. 10.1016/j.eurpolymj.2016.10.04110.1016/j.eurpolymj.2016.10.041 ↗
6. 10.1038/s41573-022-00520-510.1038/s41573-022-00520-5 ↗
7. 10.1155/2016/605814710.1155/2016/6058147 ↗
8. 10.1038/s41467-018-04999-810.1038/s41467-018-04999-8 ↗
9. 10.3390/cancers905005010.3390/cancers9050050 ↗
10. 10.1186/s40425-017-0257-y10.1186/s40425-017-0257-y ↗
11. 10.1021/acs.jmedchem.7b0087310.1021/acs.jmedchem.7b00873 ↗
12. 10.1172/jci.insight.12063110.1172/jci.insight.120631 ↗
13. 10.1084/jem.2017144010.1084/jem.20171440 ↗
14. 10.1016/j.ccr.2014.05.01610.1016/j.ccr.2014.05.016 ↗
15. 10.15252/emmm.20180934210.15252/emmm.201809342 ↗
16. 10.1371/journal.pone.010423010.1371/journal.pone.0104230 ↗
17. 10.1038/ncomms1429310.1038/ncomms14293 ↗
18. 10.1002/cbf.331910.1002/cbf.3319 ↗
19. 10.1038/nri389610.1038/nri3896 ↗
20. 10.3389/fonc.2016.0009610.3389/fonc.2016.00096 ↗
21. 10.1126/sciadv.abi712710.1126/sciadv.abi7127 ↗
22. 10.1101/cshperspect.a02227710.1101/cshperspect.a022277 ↗
23. 10.2217/crc‐2017‐000210.2217/crc‐2017‐0002 ↗
24. 10.1038/s41467-021-22965-910.1038/s41467-021-22965-9 ↗
25. 10.1056/NEJMoa150403010.1056/NEJMoa1504030 ↗
26. 10.1073/pnas.091517410710.1073/pnas.0915174107 ↗
27. 10.1042/BST036147810.1042/BST0361478 ↗
28. 10.1002/adhm.20120026810.1002/adhm.201200268 ↗
29. 10.1021/bm401141u10.1021/bm401141u ↗
30. 10.1186/s12951-018-0439-x10.1186/s12951-018-0439-x ↗
31. 10.1073/pnas.130337711010.1073/pnas.1303377110 ↗
32. 10.1016/j.jconrel.2014.11.03310.1016/j.jconrel.2014.11.033 ↗
33. 10.1038/s41565-019-0512-010.1038/s41565-019-0512-0 ↗
34. 10.1016/j.jconrel.2013.03.01010.1016/j.jconrel.2013.03.010 ↗
35. 10.1016/j.celrep.2016.04.08410.1016/j.celrep.2016.04.084 ↗
36. 10.1158/2326-6066.CIR-18-031010.1158/2326-6066.CIR-18-0310 ↗
37. 10.1038/nature2549210.1038/nature25492 ↗
38. 10.1200/JCO.2018.36.4_suppl.76410.1200/JCO.2018.36.4_suppl.764 ↗
39. 10.4049/jimmunol.150254810.4049/jimmunol.1502548 ↗
40. 10.1038/natrevmats.2016.6910.1038/natrevmats.2016.69 ↗
41. 10.4155/tde-2016-005810.4155/tde-2016-0058 ↗
42. 10.1023/B:AGEN.0000011801.98187.f210.1023/B:AGEN.0000011801.98187.f2 ↗
43. 10.1002/ddr.2026510.1002/ddr.20265 ↗
44. 10.1080/1061186090280704610.1080/10611860902807046 ↗
45. 10.1182/blood-2006-05-02358010.1182/blood-2006-05-023580 ↗
46. 10.1056/NEJMoa05142410.1056/NEJMoa051424 ↗
47. 10.1200/JCO.2016.34.15_suppl.350110.1200/JCO.2016.34.15_suppl.3501 ↗
48. 10.1002/mabi.20150002110.1002/mabi.201500021 ↗
49. 10.1016/j.eurpolymj.2019.10924610.1016/j.eurpolymj.2019.109246 ↗
50. 10.1111/cts.1253710.1111/cts.12537 ↗
51. 10.1016/j.eurpolymj.2016.09.05210.1016/j.eurpolymj.2016.09.052 ↗
52. 10.1021/acs.biomac.6b0139210.1021/acs.biomac.6b01392 ↗
53. 10.1016/j.jconrel.2007.02.01510.1016/j.jconrel.2007.02.015 ↗
54. 10.1007/s13758-011-0001-y10.1007/s13758-011-0001-y ↗
55. 10.1016/j.biomaterials.2013.10.00310.1016/j.biomaterials.2013.10.003 ↗
56. 10.1016/j.jconrel.2006.01.00610.1016/j.jconrel.2006.01.006 ↗
57. 10.1016/j.celrep.2016.04.00710.1016/j.celrep.2016.04.007 ↗
58. 10.1002/eji.20073798410.1002/eji.200737984 ↗
59. Tryba A. · Eng. Biomater. · 2018 · 21 · 16
60. 10.1021/acs.chemrev.5b0010910.1021/acs.chemrev.5b00109 ↗
61. 10.1002/anie.20150862610.1002/anie.201508626 ↗
62. 10.1210/en.2009-108210.1210/en.2009-1082 ↗
63. 10.1007/s00281-004-0167-110.1007/s00281-004-0167-1 ↗
64. 10.1038/ni92810.1038/ni928 ↗
65. 10.1016/j.coi.2006.03.01710.1016/j.coi.2006.03.017 ↗
66. 10.1038/nri167010.1038/nri1670 ↗
67. 10.1007/s10875-005-2814-210.1007/s10875-005-2814-2 ↗
68. 10.1016/j.drudis.2011.04.00610.1016/j.drudis.2011.04.006 ↗
69. 10.1038/nri137210.1038/nri1372 ↗
70. 10.1016/j.vaccine.2008.07.03510.1016/j.vaccine.2008.07.035 ↗
71. 10.1038/nnano.2017.5210.1038/nnano.2017.52 ↗
72. 10.1038/nnano.2011.14910.1038/nnano.2011.149 ↗
73. 10.1371/journal.pone.010185410.1371/journal.pone.0101854 ↗
74. 10.1016/j.vaccine.2017.03.06710.1016/j.vaccine.2017.03.067 ↗
75. 10.18632/oncotarget.1763910.18632/oncotarget.17639 ↗
76. 10.4049/jimmunol.176.12.733510.4049/jimmunol.176.12.7335 ↗
77. 10.1016/j.jconrel.2017.01.00410.1016/j.jconrel.2017.01.004 ↗
78. 10.1080/21645515.2017.142044610.1080/21645515.2017.1420446 ↗
79. 10.1016/j.ccr.2012.02.02210.1016/j.ccr.2012.02.022 ↗
80. 10.1016/j.bbcan.2014.01.00410.1016/j.bbcan.2014.01.004 ↗
81. 10.1007/s12026-017-8944-910.1007/s12026-017-8944-9 ↗
82. 10.1080/21645515.2018.143159810.1080/21645515.2018.1431598 ↗
83. 10.4049/jimmunol.170.7.380610.4049/jimmunol.170.7.3806 ↗
84. 10.1158/0008-5472.CAN-10-265110.1158/0008-5472.CAN-10-2651 ↗
85. 10.1186/s40425-018-0356-410.1186/s40425-018-0356-4 ↗
86. 10.1016/j.bbcan.2016.11.00110.1016/j.bbcan.2016.11.001 ↗
87. 10.1016/j.jconrel.2019.06.01710.1016/j.jconrel.2019.06.017 ↗
88. 10.1158/2326-6066.CIR-16-030910.1158/2326-6066.CIR-16-0309 ↗
89. 10.1200/JCO.2019.37.15_suppl.257910.1200/JCO.2019.37.15_suppl.2579 ↗
90. 10.5301/IJAO.2011.642010.5301/IJAO.2011.6420 ↗
91. 10.1016/j.biomaterials.2010.02.05710.1016/j.biomaterials.2010.02.057 ↗
92. 10.1016/j.biomaterials.2009.05.04510.1016/j.biomaterials.2009.05.045 ↗
93. 10.1172/JCI12745810.1172/JCI127458 ↗
94. 10.1136/jitc-2021-00361410.1136/jitc-2021-003614 ↗